LabCorp to Market Lung Cancer Dx from Duke | GenomeWeb
NEW YORK (GenomeWeb News) – Laboratory Corporation of America plans to commercialize a blood-based assay for early-stage lung cancer detection that was developed by Duke University Medical Center, the company said today.
Working under an exclusive license agreement, Burlington, NC-based LabCorp plans to market the serum protein assay, which is based on research published in a recent issue of the Journal of Clinical Oncology. The assay could serve as a useful complement to imaging studies, the company said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.